Who Makes Mounjaro and Zepbound: Understanding the Innovations Behind These Weight Loss Solutions

Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Eli Lilly developed tirzepatide, the active ingredient in both Mounjaro and Zepbound, as a dual GLP-1 and GIP receptor agonist that targets two distinct appetite-control pathways in the brain. Clinical trials show tirzepatide produces weight loss ranging from 21% to 24% of baseline body weight over 72 weeks, outperforming single-action semaglutide in head-to-head comparisons. PlexusDx delivers compounded tirzepatide injections from licensed 503A pharmacies to all 50 states, making this innovation accessible without insurance.

The History and Development of Tirzepatide by Eli Lilly

Eli Lilly, a pharmaceutical giant founded in 1876, invested decades in peptide science before launching tirzepatide to the market. The company identified GIP receptors as an untapped therapeutic target for metabolic disorders, building on decades of incretin research pioneered in diabetes treatment. Tirzepatide emerged from Lilly's commitment to understanding how two hormone pathways—GLP-1 and GIP—work synergistically to suppress appetite and improve insulin sensitivity simultaneously.

The FDA approved tirzepatide for diabetes management in 2022 under the brand name Mounjaro, followed by approval for weight loss as Zepbound in November 2023. This dual indication reflects the drug's potent effect on both blood sugar control and body weight reduction. Lilly's research team demonstrated that combining GLP-1 and GIP activation produces superior metabolic outcomes compared to targeting either pathway alone, setting tirzepatide apart from earlier single-agonist medications.

How Tirzepatide Works: Dual GLP-1 and GIP Receptor Action

Tirzepatide functions as a dual receptor agonist, meaning it binds to and activates two distinct hormone receptors—GIPR—that control appetite, glucose metabolism, and energy expenditure. GLP-1 receptors signal the brain to reduce hunger cues and slow stomach emptying, while GIP receptors enhance insulin secretion and improve metabolic efficiency. This dual mechanism explains why tirzepatide achieves greater weight loss than semaglutide, which activates only the GLP-1 receptor.

Studies published in the New England Journal of Medicine showed tirzepatide recipients achieved mean weight reductions of 22.5% at the highest dose, compared to 16% for semaglutide users. The medication's effect extends beyond appetite suppression—it increases energy expenditure and promotes fat oxidation at the cellular level. These mechanisms make tirzepatide particularly effective for individuals with insulin resistance or prediabetes, conditions that often accompany obesity.

Mounjaro vs. Zepbound: Understanding the Brand Names

Mounjaro and Zepbound contain identical tirzepatide formulations but carry different brand names because they target separate medical conditions—Mounjaro addresses type 2 diabetes, while Zepbound targets chronic weight management in individuals without diabetes. From a clinical standpoint, the medication itself is chemically identical; the distinction exists purely for regulatory and marketing purposes. Both medications use the same dosing schedule, starting at 2.5 mg weekly and titrating upward based on tolerance and response.

Insurance coverage and prior authorization requirements differ between the two brand names, which influences accessibility for patients. Individuals using Mounjaro for diabetes may experience weight loss as a secondary benefit, while Zepbound users pursue weight loss as the primary therapeutic goal. PlexusDx compounded tirzepatide bypasses brand name restrictions entirely, providing access regardless of insurance status or diabetes diagnosis, with consistent monthly pricing at $289/mo month-to-month, or from $249/mo on the 6-month plan.

PlexusDx Compounded Tirzepatide: Access and Personalization

PlexusDx partners with licensed 503A compounding pharmacies to deliver pharmaceutical-grade tirzepatide injections customized for individual treatment plans across all 50 states. Unlike brand-name medications requiring insurance authorization or substantial out-of-pocket costs, PlexusDx tirzepatide injections are $289/mo month-to-month, or from $249/mo on the 6-month plan with no insurance requirement, no membership fees, and HSA/FSA eligibility. The pricing model ensures your dose may need to go up as your body adapts, but your monthly cost remains stable—eliminating price surprises as treatment progresses.

PlexusDx offers optional Precision Peptide Genetic Testing for $298, analyzing 14 metabolic pathways and 150+ genetic insights relevant to GLP-1 and GIP receptor responsiveness. Testing evaluates key variants including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—genetic markers that influence individual response patterns to tirzepatide. This personalization layer helps optimize therapy selection and dosing strategy based on your unique genetic profile rather than one-size-fits-all protocols.

Safety Profile and Side Effect Management

Tirzepatide carries similar gastrointestinal side effects to other GLP-1 medications, including nausea, vomiting, and diarrhea—effects that typically diminish within 2-4 weeks as the body adjusts. Serious but rare complications include pancreatitis, gallbladder disease, and thyroid concerns; however, real-world safety data from hundreds of thousands of users demonstrates tirzepatide's overall tolerability matches or exceeds semaglutide. Gradual dose escalation—the standard 4-week titration schedule—minimizes gastrointestinal symptoms while allowing sustained weight loss.

Contraindications include personal or family history of medullary thyroid cancer and multiple endocrine neoplasia type 2, conditions that require alternative treatment approaches. PlexusDx clinical protocols emphasize baseline health screening and regular follow-up monitoring to identify adverse effects early. Most patients experience mild side effects during initial dosing, which resolve with continued use or dose adjustment, making tirzepatide a manageable option for long-term weight management.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded tirzepatide from PlexusDx the same as brand-name Mounjaro or Zepbound?

PlexusDx tirzepatide contains identical active pharmaceutical ingredient produced by licensed 503A compounding pharmacies following FDA guidelines, ensuring pharmaceutical-grade quality. While compounded versions are not FDA-approved as finished products, they use the same tirzepatide compound as brand medications and deliver equivalent clinical outcomes. The primary difference is cost—PlexusDx tirzepatide is $289 monthly month-to-month, or from $249/mo on the 6-month plan without insurance requirements, compared to brand-name costs that often exceed $1,000 monthly after insurance deductibles.

How much weight can I expect to lose with tirzepatide?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Does PlexusDx require insurance or a membership fee?

PlexusDx serves all 50 states without requiring insurance, membership fees, or prior authorization—you pay a flat monthly rate at $289/mo month-to-month, or from $249/mo on the 6-month plan for tirzepatide injection. Your dose may need adjustment as treatment progresses, but your price remains stable month-to-month. HSA and FSA accounts cover PlexusDx medications, and you maintain complete privacy and control over your treatment without insurance involvement.

What genetic factors affect how well tirzepatide works?

PlexusDx Precision Peptide Genetic Testing analyzes variants in GIPR and FTO, and MC4R genes that influence tirzepatide response and weight loss trajectory. The FTO rs9939609 variant, for example, associates with increased appetite signaling, potentially predicting stronger GLP-1 agonist response in carriers. Testing maps 49 peptides across 14 metabolic pathways, helping PlexusDx clinicians optimize your personalized treatment protocol based on your unique genetic architecture.

How quickly will I see weight loss results with tirzepatide?

Most patients notice appetite suppression within the first week at starting doses (2.5 mg), with measurable weight loss appearing within 2-4 weeks. Significant weight loss typically accelerates between weeks 4-12 as doses increase during titration, with the most dramatic results occurring between months 2-6 of treatment. Continued dose escalation through month 4 (reaching 15 mg) produces sustained weight loss through month 6 and beyond, with plateau typically occurring after 6-12 months of stable dosing.

Related Reading

• Mounjaro For Weight Loss 2
• Weight Loss Mounjaro
• Mounjaro Weight Loss By Week
• Wegovy Vs Zepbound Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.